SALMETEROL XINAFOATE

Details

Stereochemistry	RACEMIC
Molecular Formula	C25H37NO4.C11H8O3
Molecular Weight	603.745
Optical Activity	( + / - )
Defined Stereocenters	0 / 1
E/Z Centers	0
Charge	0

SHOW SMILES / InChI

Structure Search

SMILES

OC(=O)C1=CC=C2C=CC=CC2=C1O.OCC3=CC(=CC=C3O)C(O)CNCCCCCCOCCCCC4=CC=CC=C4

InChI

InChIKey=XTZNCVSCVHTPAI-UHFFFAOYSA-N

InChI=1S/C25H37NO4.C11H8O3/c27-20-23-18-22(13-14-24(23)28)25(29)19-26-15-7-1-2-8-16-30-17-9-6-12-21-10-4-3-5-11-21;12-10-8-4-2-1-3-7(8)5-6-9(10)11(13)14/h3-5,10-11,13-14,18,25-29H,1-2,6-9,12,15-17,19-20H2;1-6,12H,(H,13,14)

HIDE SMILES / InChI

Molecular Formula	C11H8O3
Molecular Weight	188.1794
Charge	0
Count

Stereochemistry	ACHIRAL
Additional Stereochemistry	No
Defined Stereocenters	0 / 0
E/Z Centers	0
Optical Activity	NONE

Molecular Formula	C25H37NO4
Molecular Weight	415.5656
Charge	0
Count

Stereochemistry	RACEMIC
Additional Stereochemistry	No
Defined Stereocenters	0 / 1
E/Z Centers	0
Optical Activity	( + / - )

Description
Sources: http://www.accessdata.fda.gov/drugsatfda_docs/label/2004/20236s030,20692s026lbl.pdf
Curator's Comment: description was created based on several sources, including: https://www.drugs.com/mtm/salmeterol-inhalation.html http://www.rxlist.com/serevent-diskus-drug.htm http://www.wikidoc.org/index.php/Salmeterol

Salmeterol is a long-acting beta2-adrenergic agonist. Although beta2-adrenoceptors are the predominant adrenergic receptors in bronchial smooth muscle and beta1-adrenoceptors are the predominant receptors in the heart, there are also beta2-adrenoceptors in the human heart comprising 10% to 50% of the total beta-adrenoceptors. The precise function of these is not yet established, but they raise the possibility that even highly selective beta2-agonists may have cardiac effects. It is FDA approved for the treatment of asthma, prevention of exercise-induced bronchospasm, maintenance treatment of chronic obstructive pulmonary disease. Common adverse reactions include musculoskeletal pain, headache, influenza, nasal/sinus congestion, pharyngitis, rhinitis, tracheitis/bronchitis, cough, throat irritation, viral respiratory infection. Salmeterol should be administered with extreme caution to patients being treated with monoamine oxidase inhibitors or tricyclic antidepressants, or within 2 weeks of discontinuation of such agents, because the action of salmeterol on the vascular system may be potentiated by these agents. Coadministration of salmeterol and ketoconazole was associated with more frequent increases in QTc duration compared with salmeterol and placebo administration.

CNS Activity

Originator

Approval Year

Targets

Primary Target	Pharmacology	Condition	Potency
Beta-2 adrenergic receptor 203 Target ID: CHEMBL210 Sources: http://www.accessdata.fda.gov/drugsatfda_docs/label/2004/20236s030,20692s026lbl.pdf	Agonist 2678		1.5 nM [Kd]

Conditions

Condition	Modality	Highest Phase	Product
Asthma 241 Sources: http://www.accessdata.fda.gov/drugsatfda_docs/label/2004/20236s030,20692s026lbl.pdf	Palliative	Approved 8429	SEREVENT Approved Use ADVAIR DISKUS is a combination product containing a corticosteroid and a LABA indicated for: Treatment of asthma in patients aged 4 years and older. (1.1) Maintenance treatment of airflow obstruction and reducing exacerbations in patients with chronic obstructive pulmonary disease (COPD). (1.2) Important limitation: Not indicated for the relief of acute bronchospasm. (1.1, 1.2) 1.1 Treatment of Asthma ADVAIR DISKUS is indicated for the treatment of asthma in patients aged 4 years and older. Long-acting beta2-adrenergic agonists (LABAs), such as salmeterol, one of the active ingredients in ADVAIR DISKUS, increase the risk of asthma-related death. Available data from controlled clinical trials suggest that LABAs increase the risk of asthma-related hospitalization in pediatric and adolescent patients [see Warnings and Precautions (5.1) Launch Date 1994
Chronic obstructive pulmonary disease 174 Sources: http://www.accessdata.fda.gov/drugsatfda_docs/label/2004/20236s030,20692s026lbl.pdf	Palliative	Approved 8429	SEREVENT Approved Use ADVAIR DISKUS is a combination product containing a corticosteroid and a LABA indicated for: Treatment of asthma in patients aged 4 years and older. (1.1) Maintenance treatment of airflow obstruction and reducing exacerbations in patients with chronic obstructive pulmonary disease (COPD). (1.2) Important limitation: Not indicated for the relief of acute bronchospasm. (1.1, 1.2) 1.1 Treatment of Asthma ADVAIR DISKUS is indicated for the treatment of asthma in patients aged 4 years and older. Long-acting beta2-adrenergic agonists (LABAs), such as salmeterol, one of the active ingredients in ADVAIR DISKUS, increase the risk of asthma-related death. Available data from controlled clinical trials suggest that LABAs increase the risk of asthma-related hospitalization in pediatric and adolescent patients [see Warnings and Precautions (5.1) Launch Date 1994
Exercise-induced bronchospasm 2 Sources: http://www.accessdata.fda.gov/drugsatfda_docs/label/2004/20236s030,20692s026lbl.pdf	Preventing	Approved 8429	SEREVENT Approved Use ADVAIR DISKUS is a combination product containing a corticosteroid and a LABA indicated for: Treatment of asthma in patients aged 4 years and older. (1.1) Maintenance treatment of airflow obstruction and reducing exacerbations in patients with chronic obstructive pulmonary disease (COPD). (1.2) Important limitation: Not indicated for the relief of acute bronchospasm. (1.1, 1.2) 1.1 Treatment of Asthma ADVAIR DISKUS is indicated for the treatment of asthma in patients aged 4 years and older. Long-acting beta2-adrenergic agonists (LABAs), such as salmeterol, one of the active ingredients in ADVAIR DISKUS, increase the risk of asthma-related death. Available data from controlled clinical trials suggest that LABAs increase the risk of asthma-related hospitalization in pediatric and adolescent patients [see Warnings and Precautions (5.1) Launch Date 1994

C_max

Value	Dose	Co-administered	Analyte	Population
319 pg/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/29493402/	50 μg single, oral dose: 50 μg route of administration: Oral experiment type: SINGLE co-administered: FLUTICASONE PROPIONATE	FLUTICASONE PROPIONATE	SALMETEROL plasma	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED
167 pg/mL DRUG LABEL https://www.accessdata.fda.gov/drugsatfda_docs/label/2007/020692s028lbl.pdf	50 μg 2 times / day multiple, oral dose: 50 μg route of administration: Oral experiment type: MULTIPLE co-administered:		SALMETEROL plasma	Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN

AUC

Value	Dose	Co-administered	Analyte	Population
464 pg × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/29493402/	50 μg single, oral dose: 50 μg route of administration: Oral experiment type: SINGLE co-administered: FLUTICASONE PROPIONATE	FLUTICASONE PROPIONATE	SALMETEROL plasma	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED

T_1/2

Value	Dose	Co-administered	Analyte	Population
10.72 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/29493402/	50 μg single, oral dose: 50 μg route of administration: Oral experiment type: SINGLE co-administered: FLUTICASONE PROPIONATE	FLUTICASONE PROPIONATE	SALMETEROL plasma	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED
5.5 h DRUG LABEL https://www.accessdata.fda.gov/drugsatfda_docs/label/2007/020692s028lbl.pdf	50 μg 2 times / day multiple, oral dose: 50 μg route of administration: Oral experiment type: MULTIPLE co-administered:		SALMETEROL plasma	Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN

F_unbound

Value	Dose	Co-administered	Analyte	Population
4% DRUG LABEL https://www.accessdata.fda.gov/drugsatfda_docs/label/2007/020692s028lbl.pdf	50 μg 2 times / day multiple, oral dose: 50 μg route of administration: Oral experiment type: MULTIPLE co-administered:		SALMETEROL plasma	Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN

Doses

Dose	Population	Adverse events
84 ug 2 times / day multiple, respiratory Dose: 84 ug, 2 times / day Route: respiratory Route: multiple Dose: 84 ug, 2 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/7909285/	unhealthy, 30 n = 31 Health Status: unhealthy Condition: asthma Age Group: 30 Sex: M+F Population Size: 31 Sources: https://pubmed.ncbi.nlm.nih.gov/7909285/	Other AEs: Headache, Dizziness... Other AEs: Headache (5 patients) Dizziness (2 patients) Tremor (5 patients) Palpitations (1 patient) Muscle cramps (1 patient) Sources: https://pubmed.ncbi.nlm.nih.gov/7909285/
400 ug single, respiratory Dose: 400 ug Route: respiratory Route: single Dose: 400 ug Sources: https://pubmed.ncbi.nlm.nih.gov/1349491/	healthy, 34.3 n = 10 Health Status: healthy Age Group: 34.3 Sex: M Population Size: 10 Sources: https://pubmed.ncbi.nlm.nih.gov/1349491/	Other AEs: Headache, Tremor... Other AEs: Headache (5 patients) Tremor (5 patients) Palpitations (3 patients) Sources: https://pubmed.ncbi.nlm.nih.gov/1349491/
50 ug 2 times / day multiple, respiratory Recommended Dose: 50 ug, 2 times / day Route: respiratory Route: multiple Dose: 50 ug, 2 times / day Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/020692s047lbl.pdf	unhealthy, 4-11 n = 211 Health Status: unhealthy Condition: asthma Age Group: 4-11 Population Size: 211 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/020692s047lbl.pdf	Other AEs: Ear disorder, Pharyngitis... Other AEs: Ear disorder (4%) Pharyngitis (6%) Headache (17%) Asthma (4%) Skin rash (4%) Urticaria (3%) Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/020692s047lbl.pdf
50 ug 2 times / day multiple, respiratory Recommended Dose: 50 ug, 2 times / day Route: respiratory Route: multiple Dose: 50 ug, 2 times / day Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/020692s047lbl.pdf	unhealthy, >12 n = 149 Health Status: unhealthy Condition: asthma Age Group: >12 Population Size: 149 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/020692s047lbl.pdf	Other AEs: Nasal sinus congestion, Rhinitis... Other AEs: Nasal sinus congestion (9%) Rhinitis (5%) Headache (13%) Asthma (3%) Tracheobronchitis (7%) Influenza (5%) Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/020692s047lbl.pdf
50 ug 2 times / day multiple, respiratory Recommended Dose: 50 ug, 2 times / day Route: respiratory Route: multiple Dose: 50 ug, 2 times / day Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/020692s047lbl.pdf	unhealthy n = 341 Health Status: unhealthy Condition: COPD Population Size: 341 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/020692s047lbl.pdf	Other AEs: Hypertension, Throat irritation... Other AEs: Hypertension (4%) Throat irritation (7%) Congestion nasal (4%) Sinusitis (4%) Ear disorder (3%) Nausea and vomiting (3%) Cough (5%) Rhinitis (4%) Respiratory tract infection viral (5%) Musculoskeletal pain (12%) Muscle cramps (3%) Headache (14%) Dizziness (4%) Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/020692s047lbl.pdf

AEs

Overview

CYP3A4	CYP2C9	CYP2D6	hERG
substrate 1737		substrate 1217	inhibitor 1612

OverviewOther

Other Inhibitor	Other Substrate	Other Inducer
MRP2 383 MRP3 157 MRP4 204 OCT3 150 P-gp 1461 CYP2C8 911 CYP2B6 810 OCT1 512 OCT2 647 BSEP 402 ALDH1 40	CYP1A2 1054 CYP2C8/9 2 CYP2E1 667 CYP3A5 395 CYP3A7 110

Drug as perpetrator

Target	Modality	Activity
BSEP 403	inhibitor 3277 Sources: https://pubmed.ncbi.nlm.nih.gov/23956101/	no [IC50 >133 uM]
MRP2 475	inhibitor 3277 Sources: https://pubmed.ncbi.nlm.nih.gov/23956101/	no [IC50 >133 uM]
MRP3 207	inhibitor 3277 Sources: https://pubmed.ncbi.nlm.nih.gov/23956101/	no [IC50 >133 uM]
MRP4 238	inhibitor 3277 Sources: https://pubmed.ncbi.nlm.nih.gov/23956101/	no [IC50 >133 uM]
OCT2 648	inhibitor 3277 Sources: https://go.drugbank.com/drugs/DB00938, https://pubmed.ncbi.nlm.nih.gov/25751092/	weak
OCT3 150	inhibitor 3277 Sources: https://go.drugbank.com/drugs/DB00938, https://pubmed.ncbi.nlm.nih.gov/25751092/	weak
ALDH1 40	inhibitor 3277 Sources: https://www.ebi.ac.uk/chembl/g/#browse/activities/full_state/eyJsaXN0Ijp7InNldHRpbmdzX3BhdGgiOiJFU19JTkRFWEVTX05PX01BSU5fU0VBUkNILkFDVElWSVRZIiwiY3VzdG9tX3F1ZXJ5IjoidGFyZ2V0X2NoZW1ibF9pZDpDSEVNQkwzNTc3IiwidXNlX2N1c3RvbV9xdWVyeSI6dHJ1ZSwic2VhcmNoX3Rlcm0iOiIiLCJ0ZXh0X2ZpbHRlciI6IkNIRU1CTDEwODI2MDcifX0%3D	yes [Activation 25.1189 uM]
CYP2C8 965	inhibitor 3277 Sources: https://pubmed.ncbi.nlm.nih.gov/15601807/	yes [IC50 1.87 uM]
OCT1 543	inhibitor 3277 Sources: https://go.drugbank.com/drugs/DB00938, https://pubmed.ncbi.nlm.nih.gov/25751092/	yes [IC50 47.8 uM]
CYP2B6 1001	inhibitor 3277 Sources: https://pubmed.ncbi.nlm.nih.gov/17101742/	yes
P-gp 1650	inhibitor 3277 Sources: https://pubmed.ncbi.nlm.nih.gov/16997908/	yes

Drug as victim

Target	Modality	Activity	Clinical evidence
CYP1A2 1054	substrate 3367 Sources: https://pubmed.ncbi.nlm.nih.gov/8723736/	no
CYP2C8/9 2	substrate 3367 Sources: https://pubmed.ncbi.nlm.nih.gov/8723736/	no
CYP2D6 1217	substrate 3367 Sources: https://pubmed.ncbi.nlm.nih.gov/8723736/	no
CYP2E1 667	substrate 3367 Sources: https://pubmed.ncbi.nlm.nih.gov/8723736/	unlikely
CYP3A5 395	substrate 3367 Sources: https://ncit-stage.nci.nih.gov/ncitbrowser/pages/concept_details.jsf?dictionary=NCI_Thesaurus&version=21.02d&code=C29443&ns=ncit&type=relationship&key=null&b=1&n=0&vse=null	yes
CYP3A7 110	substrate 3367 Sources: https://ncit-stage.nci.nih.gov/ncitbrowser/pages/concept_details.jsf?dictionary=NCI_Thesaurus&version=21.02d&code=C29443&ns=ncit&type=relationship&key=null&b=1&n=0&vse=null	yes
CYP3A4 1737	substrate 3367 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/020692s047lbl.pdf#page=13, https://ncit-stage.nci.nih.gov/ncitbrowser/pages/concept_details.jsf?dictionary=NCI_Thesaurus&version=21.02d&code=C29443&ns=ncit&type=relationship&key=null&b=1&n=0&vse=null Page: 13-14, 21-22	yes	yes (co-administration study) Comment: Coadministration of inhaled Salmetrol and oral ketoconazole (strong CYP3A4 inhibitor) for 7 days increased Salmetrol AUC by 16-fold and Cmax by 1.4-fold. Coadministration of Erythromycin (moderate CYP3A4 inhibitor) increased inhaled Salmeterol Cmax,ss by 40% (3.6-beat/min in heart rate, 5.8-msec increase in QTc interval). Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/020692s047lbl.pdf#page=13, https://ncit-stage.nci.nih.gov/ncitbrowser/pages/concept_details.jsf?dictionary=NCI_Thesaurus&version=21.02d&code=C29443&ns=ncit&type=relationship&key=null&b=1&n=0&vse=null Page: 13-14, 21-22

Tox targets

Target	Modality	Activity	Metabolite	Clinical evidence
hERG 1647	inhibitor 1626 Sources: https://www.ebi.ac.uk/chembl/g/#browse/activities/full_state/eyJsaXN0Ijp7InNldHRpbmdzX3BhdGgiOiJFU19JTkRFWEVTX05PX01BSU5fU0VBUkNILkFDVElWSVRZIiwiY3VzdG9tX3F1ZXJ5IjoidGFyZ2V0X2NoZW1ibF9pZDpDSEVNQkwyNDAiLCJ1c2VfY3VzdG9tX3F1ZXJ5Ijp0cnVlLCJzZWFyY2hfdGVybSI6IiIsInRleHRfZmlsdGVyIjoiQ0hFTUJMMTA4MjYwNyJ9fQ%3D%3D, https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/020692s047lbl.pdf#page=22 Page: (Label) 22

Sourcing

Vendor/Aggregator	ID	URL
001 Chemical	DY447694	https://www.001chemical.com/chem/89365-50-4
AA Blocks	AA003AUE	https://www.aablocks.com/goods/Goods/detail?id=AA003AUE
AEchem Scientific Corp., USA	AE1-000626	http://www.aechemsc.com/info_products/AE1-000626.php
AHH Chemical co.,ltd	MT-01629	http://www.ahhchemical.com/product/MT-01629.html
AHH Chemical co.,ltd	MT-22224	http://www.ahhchemical.com/product/MT-22224.html
AK Scientific, Inc. (AKSCI)	K590	http://www.aksci.com/item_detail.php?cat=K590
Aaron Chemicals	AR003BM6	http://www.aaronchem.com/89365-50-4
Achemica	ACMC-1C1VM	http://www.achemica.com/prodinfo/?id=79389
Achemtek	0104-001738	http://www.achemtek.com/89365-50-4
Acorn PharmaTech	ACN-040075	http://www.acornpharmatech.com/
Alfa Chemistry	AP1330076522	https://reagents.alfa-chemistry.com/product/salmeterol-related-compound-h-cas-1330076-52-2-3896.html
Alfa Chemistry	136112-01-1	https://www.alfa-chemistry.com/cas_136112-01-1.htm
Ambeed	A728769	https://www.ambeed.com/products/94749-08-3.html
Angel Pharmatech	AG153148	http://www.angelpharmatech.com/89365-50-4.html
Angene	AGN-PC-0VOWRZ	http://www.angenechemical.com/productshow/AGN-PC-0VOWRZ.html
Ark Pharm	AK173141	http://www.arkpharminc.com/products/89365-50-4.html
Ark Pharma Scientific Limited	N-2877	http://www.arkpharmtech.com/product/244416.html
Aurora Fine Chemicals LLC	A12.866.668	http://online.aurorafinechemicals.com/info?ID=A12.866.668
AvaChem Scientific	2784B	http://www.avachem.com/productSearch.asp?2784B
BLD Pharm	BD150785	http://www.bldpharm.com/products/94749-08-3.html
BOC Sciences	497063-94-2	https://www.bocsci.com/salmeterol-d3-cas-497063-94-2-item-482701.html
BioChemPartner	BCP04199	http://www.biochempartner.com/89365-50-4-BCP04199
BioSynth	Q-101428	https://www.biosynth.com/en/products/life-science/other-biochemicals/products/Q-101428.html
Boerchem	BC202639	http://www.boerchem.com/?product_34051.html
CSNpharm	CSN11887	https://www.csnpharm.com/products/salmeterol-xinafoate.html
Chem Scene	CS-2815	http://www.chemscene.com/89365-50-4.html
ChemMol	44001319	http://www.chemmol.com/chemmol/44001319.html
ChemMol	49401177	http://www.chemmol.com/chemmol/49401177.html
ChemMol	97900683	http://www.chemmol.com/chemmol/97900683.html
ChemMol	99162002	http://www.chemmol.com/chemmol/99162002.html
Chemspace	CSSB00000047424	https://chem-space.com/CSSB00000047424
Clearsynth	CS-T-61226	https://www.clearsynth.com/en/CST61226.html
Clearsynth	CS-T-85804	https://www.clearsynth.com/en/CST85804.html
DC Chemicals	DC8610	http://www.dcchemicals.com/product_show-Salmeterol.html
Excenen	EX-A4409	https://www.excenen.com/searchresultlist.php?id=EX-A4409
Finetech	FT-0674509	http://www.finetechnology-ind.com/prod/detail/pub/1330076-52-2.html
Finetech	FT-0674508	http://www.finetechnology-ind.com/prod/detail/pub/497063-94-2.html
Hairui	HR132921	http://www.hairuichem.com/en/product/89365-50-4.html
LGC Standards	DRE-A16904900AL-100	https://www.lgcstandards.com/US/en/p/DRE-A16904900AL-100
LGC Standards	DRE-C16904900	https://www.lgcstandards.com/US/en/p/DRE-C16904900
Lab Network	LN01295079	https://labnetwork.com/frontend-app/p/#!/moleculedetails/LN01295079
MedChem Express	HY-14302	https://www.medchemexpress.com/Salmeterol.html
Molcore	MC447694	https://www.molcore.com/product/89365-50-4
MuseChem	I005348	https://www.musechem.com/product/I005348.html
MuseChem	R052751	https://www.musechem.com/product/R052751.html
OChem	5082	http://www.ocheminc.com/index.php?act=psearch&pid=365S504
Smolecule	S542353	http://www.smolecule.com/products/s542353
Smolecule	S793339	https://www.smolecule.com/products/s793339
THE BioTek	bt-281527	https://www.thebiotek.com/product/inhibitors/bt-281527
THE BioTek	bt-459092	https://www.thebiotek.com/product/others/bt-459092
TripleBond	CS0057	http://www.triplebond-canada.com/prod/1591/
Yuhao Chemical	RT12961	http://www.chemyuhao.com/136112-01-1.html
Yuhao Chemical	RT2765	http://www.chemyuhao.com/1391051-88-9.html
Yuhao Chemical	YH93795	http://www.chemyuhao.com/89365-50-4.html
abcr GmbH	AB492509	http://www.abcr.com/shop/en/AB492509
eNovation Chemicals	D371569	http://www.enovationchem.com/productDetails.asp?productID=D371569
eNovation Chemicals	D565765	https://www.enovationchem.com/ProductDetails.asp?ProductID=D565765
eNovation Chemicals	D633111	https://www.enovationchem.com/ProductDetails.asp?ProductID=D633111
iChemical	EBD39669	http://www.ichemical.com/products/89365-50-4.html?utm_source=PubChem&utm_medium=website&utm_campaign=product%20catalogs

PubMed

Title	Date	PubMed
Salmeterol: a four week study of a long-acting beta-adrenoceptor agonist for the treatment of reversible airways disease.	1991 Nov	1687131
Effects of salmeterol and terbutaline on IgE-mediated dermal reactions and inflammatory events in skin chambers in atopic patients.	1996 Sep	8899116
Salmeterol versus theophylline in the treatment of asthma.	1997 May	9164358
Asthma therapy modulates priming-associated blood eosinophil responsiveness in allergic asthmatics.	1999 Oct	10573242
Comparison of the bronchodilating effect of salmeterol and zafirlukast in combination with that of their use as single treatments in asthma and chronic obstructive pulmonary disease.	2001	11694805
Characterization of agonist stimulation of cAMP-dependent protein kinase and G protein-coupled receptor kinase phosphorylation of the beta2-adrenergic receptor using phosphoserine-specific antibodies.	2004 Jan	14722251
Synergistic effects of fluticasone propionate and salmeterol on in vitro T-cell activation and apoptosis in asthma.	2004 Nov	15536434
Outcomes associated with initiation of different controller therapies in a Medicaid asthmatic population: a retrospective data analysis.	2005 Feb	15801326
Meta-analysis: effect of long-acting beta-agonists on severe asthma exacerbations and asthma-related deaths.	2006 Jun 20	16754916
Comparative safety of long-acting inhaled bronchodilators: a cohort study using the UK THIN primary care database.	2007	18035867
Budesonide prevents cytokine-induced decrease of the relaxant responses to formoterol and terbutaline, but not to salmeterol, in mouse trachea.	2010 Apr	20061444
[Cushing's syndrome during HIV treatment: pharmacological interaction during use of ritonavir].	2013	23548184

Patents

Sample Use Guides

In Vivo Use Guide

Asthma and Chronic Obstructive Pulmonary Disease: the usual dosage for adults and children 4 years of age and older is 1 inhalation (50 mcg) twice daily (morning and evening, approximately 12 hours apart). Exercise-Induced Bronchospasm: One inhalation of SEREVENT DISKUS at least 30 minutes before exercise.

Route of Administration: Respiratory

In Vitro Use Guide

Since fibroblasts express beta2-adrenoreceptors, the effects of different concentrations (0.1-100 nM) of salmeterol on lung fibroblast proliferation and adhesion molecule expression were evaluated. A significant downregulation of ICAM-1 or H-CAM expression was demonstrated in the presence of Salmeterol, at all concentrations tested (0.1-100 nM; p<0.01).

Substance Class	Chemical Created by `admin` on `Fri Dec 15 16:21:13 GMT 2023` Edited by `admin` on `Fri Dec 15 16:21:13 GMT 2023`
Record UNII	6EW8Q962A5
Record Status	`Validated (UNII)`
Record Version

Download

Name

Type

Language

SALMETEROL XINAFOATE

Official Name

English

SALMETEROL XINAFOATE [EP MONOGRAPH]

Common Name

English

GR-33343 G

Code

English

SALMETEROL XINAFOATE [USP-RS]

Common Name

English

GR 33343 G

Code

English

SALMETEROL 1-HYDROXY-2-NAPHTHOATE [MI]

Common Name

English

SALMETEROL XINAFOATE COMPONENT OF AIRDUO RESPICLICK

Common Name

English

SALMETEROL XINAFOATE [JAN]

Common Name

English

SALMETEROL XINAFOATE [USP MONOGRAPH]

Common Name

English

SALMETEROL XINAFOATE [EP IMPURITY]

Common Name

English

SEREVENT

Brand Name

English

SALMETEROL XINAFOATE [MART.]

Common Name

English

ADVAIR HFA COMPONENT SALMETEROL XINAFOATE

Common Name

English

ADVAIR COMPONENT SALMETEROL XINAFOATE

Brand Name

English

SALMETEROL XINAFOATE [USAN]

Common Name

English

AIRDUO RESPICLICK COMPONENT SALMETEROL XINAFOATE

Brand Name

English

(±)-4-HYDROXY-.ALPHA.(SUP 1)-(((6-(4-PHENYLBUTOXY)HEXYL)AMINO)METHYL)-M-XYLENE-.ALPHA.,.ALPHA.'-DIOL 1-HYDROXY-2-NAPHTHOATE

Common Name

English

SALMETEROL XINAFOATE [ORANGE BOOK]

Common Name

English

SALMETEROL XINAFOATE COMPONENT OF ADVAIR

Brand Name

English

LIPO-102 COMPONENT SALMETEROL XINAFOATE

Common Name

English

GR-33343X

Code

English

SALMETEROL XINAFOATE COMPONENT OF ADVAIR HFA

Common Name

English

SALMETEROL 1-HYDROXY-2-NAPHTHOATE

Common Name

English

1,3-BENZENEDIMETHANOL, 4-HYDROXY-.ALPHA.(SUP 1)-(((6-(4-PHENYLBUTOXY)HEXYL)AMINO)METHYL)-, (±)-, 1-HYDROXY-2-NAPHTHALENECARBOXYLATE

Common Name

English

SALMETEROL XINAFOATE [VANDF]

Common Name

English

Salmeterol xinafoate [WHO-DD]

Common Name

English

Classification Tree Code System Code

NCI_THESAURUS

C319